Agensys Inc v. Assistant Controller Of Patents Asnd Designs

In the high-stakes world of biotechnology, where a single molecular tweak can be worth billions, the line between a true invention and a routine laboratory improvement is fiercely contested. When the patent office draws that line too conservatively, innovators are forced into courtrooms to defend the very value of their discoveries. The case of Agensys Inc versus the Assistant Controller of Patents and Designs is a striking example of this tension, raising a critical question for every biotech founder: when does an improved antibody cross the threshold from obvious refinement to patent-worthy invention?

Agensys Inc, a biotechnology company, found itself on the wrong side of a rejection order from the Assistant Controller of Patents and Designs. The Controller had turned down Agensys's patent application for a monoclonal antibody invention, citing Section 3(d) of the Patents Act, 1970, a provision that screens out claims lacking genuine inventive merit. Section 3(d) is the legal gatekeeper designed to prevent evergreening and to ensure that only inventions demonstrating a real technical contribution earn patent protection. Agensys, convinced that its invention deserved recognition, escalated the matter by filing an appeal to challenge the impugned order.

Agensys built its case around a single, powerful argument: its monoclonal antibody was not just another iteration of existing science. The company contended that the invention demonstrated a concrete technical effect, specifically improved affinity and cross-reactivity, that the Controller had failed to properly consider. In essence, Agensys argued that its antibody bound to its target in a meaningfully superior way, and that this enhanced performance was precisely the kind of technical advancement the patent system is meant to reward. The legal friction centered on whether this improved binding profile rose to the level of an inventive step, or whether it was simply an expected outcome that any skilled researcher in the field would have anticipated. The Controller's position, embedded in the original rejection, suggested the latter: that the antibody did not demonstrate the kind of surprising or non-obvious technical contribution required under the law.

As of the proceedings, the matter remained pending before the court. The central legal question before the bench was whether the technical effect cited by Agensys, improved affinity and cross-reactivity, satisfied the inventive step requirement under Section 3(d) of the Patents Act, 1970. The court's eventual reasoning will need to grapple with the established principle that for an antibody binding to a known antigen to qualify as inventive, it must demonstrate a surprising technical effect, such as improved affinity or reduced toxicity, unless the field offered no reasonable expectation of success in the first place. Until the bench delivers its ruling, the fate of Agensys's patent application hangs in the balance.

For biotech founders and IP professionals working on antibody-based inventions, this case offers a clear and urgent lesson: simply showing that your antibody binds well is not enough to secure patent protection. To overcome rejections under Section 3(d), you must be prepared to demonstrate a surprising, non-obvious technical effect, whether that is dramatically improved affinity, reduced toxicity, or some other measurable advantage that a skilled person in the field would not have predicted. Document your experimental data meticulously, benchmark your results against prior art, and articulate clearly why your invention represents a genuine leap rather than a routine optimization. In the antibody space, the difference between a granted patent and a rejected application often comes down to how convincingly you can prove that your science surprised even the experts.